Suppr超能文献

人类内毒素血症:一种用于机制洞察和治疗靶点研究的模型。

Human endotoxemia: a model for mechanistic insight and therapeutic targeting.

作者信息

Lowry Stephen F

机构信息

UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903-0019, USA.

出版信息

Shock. 2005 Dec;24 Suppl 1:94-100. doi: 10.1097/01.shk.0000191340.23907.a1.

Abstract

The diversity of phenotypic manifestations, comorbidities, and therapeutic algorithms in patients with severe inflammation have confounded efforts to translate mechanistic insights from the bench top to the bedside. This dilemma has negatively impacted upon many therapeutic interventions that exhibited seemingly well-reasoned preclinical portfolios. Prudence urges the assessment of potent immunoregulatory therapies, wherever possible, in models that replicate the clinical phenotype absent overt manifestations of genetically or environmentally modified processes. The healthy human model of endotoxin administration (systemic or endobronchial) provides such an opportunity and has been used to great advantage for gaining insight into mechanisms of disease and for determination of therapeutic signal strength. When thoughtfully interpreted, the model may provide proof of principle as well as lessen the unpredictability of clinical responses. Although the broad characteristics of this model are well described in the literature, it is recognized that this model does not fully replicate the magnitude of initial inflammatory stress nor the latent spectrum of inflammation/sepsis-inducible organ system pathologies. Nevertheless, the similarities between the early, transient clinical phenotype, inducible physiochemical change, and biochemical pathway activation of this model to the early hyperdynamic phase of resuscitated injury and infection are striking. Rational testing of a therapeutic mechanism requires a quantifiable and reproducibly altered marker of the hypothetical mechanism. Given the modest nature of endotoxin induced insult, interventions that demonstrate target specific efficacy in conjunction with attenuated phenotype responses are more likely to exhibit efficacy within lower risk patient populations. By contrast, the model cannot predict clinical efficacy among higher risk patients nor in those who have endured extended periods of inflammatory stress.

摘要

重症炎症患者的表型表现、合并症及治疗算法的多样性,使得将实验室的机制性见解转化到临床实践的努力变得复杂。这一困境对许多有着看似合理的临床前研究组合的治疗干预措施产生了负面影响。谨慎起见,应尽可能在能复制临床表型而无基因或环境修饰过程明显表现的模型中评估有效的免疫调节疗法。健康人内毒素给药模型(全身或支气管内给药)提供了这样一个机会,并已被大量用于深入了解疾病机制及确定治疗信号强度。经过深思熟虑的解读后,该模型可提供原理证明,并减少临床反应的不可预测性。尽管该模型的广泛特征在文献中有详细描述,但人们认识到该模型并不能完全复制初始炎症应激的程度,也无法复制炎症/脓毒症诱导的器官系统病理的潜在范围。然而,该模型早期短暂的临床表型、可诱导的理化变化以及生化途径激活与复苏后损伤和感染的早期高动力阶段之间的相似性十分显著。对治疗机制进行合理测试需要一个可量化且可重复改变的假设机制标志物。鉴于内毒素诱导的损伤程度较轻,在减轻表型反应的同时显示出靶点特异性疗效的干预措施更有可能在低风险患者群体中展现疗效。相比之下,该模型无法预测高风险患者或经历长时间炎症应激患者的临床疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验